These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Molecular characterization of RET/PTC3; a novel rearranged version of the RETproto-oncogene in a human thyroid papillary carcinoma. Santoro M; Dathan NA; Berlingieri MT; Bongarzone I; Paulin C; Grieco M; Pierotti MA; Vecchio G; Fusco A Oncogene; 1994 Feb; 9(2):509-16. PubMed ID: 8290261 [TBL] [Abstract][Full Text] [Related]
11. Prevalence, significance, and biological behavior of ret/PTC1 associated papillary thyroid carcinoma. Cetta F J Clin Endocrinol Metab; 1997 May; 82(5):1650. PubMed ID: 9141569 [No Abstract] [Full Text] [Related]
12. RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. Tallini G; Santoro M; Helie M; Carlomagno F; Salvatore G; Chiappetta G; Carcangiu ML; Fusco A Clin Cancer Res; 1998 Feb; 4(2):287-94. PubMed ID: 9516913 [TBL] [Abstract][Full Text] [Related]
13. Rearrangements of RET and NTRK1 tyrosine kinase receptors in papillary thyroid carcinomas. Pierotti MA; Vigneri P; Bongarzone I Recent Results Cancer Res; 1998; 154():237-47. PubMed ID: 10027004 [TBL] [Abstract][Full Text] [Related]
14. Different significance of ret/PTC(1) and ret/PTC(3) rearrangements in thyroid carcinogenesis: lesson from two subgroups of patients with papillary thyroid carcinomas showing the highest incidence of ret/PTC activation. Cetta F; Gori M; Montalto G; Zuckermann M; Toti P J Clin Endocrinol Metab; 2001 Mar; 86(3):1429. PubMed ID: 11238550 [No Abstract] [Full Text] [Related]
15. Correspondence re: G. Tallini et al., RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotype. Clin. Cancer Res., 4:287-294, 1998. Soares P; Sobrinho-Simões M Clin Cancer Res; 1999 Nov; 5(11):3724-5. PubMed ID: 10589793 [No Abstract] [Full Text] [Related]
17. Low frequency of rearrangements of the ret and trk proto-oncogenes in Japanese thyroid papillary carcinomas. Wajjwalku W; Nakamura S; Hasegawa Y; Miyazaki K; Satoh Y; Funahashi H; Matsuyama M; Takahashi M Jpn J Cancer Res; 1992 Jul; 83(7):671-5. PubMed ID: 1381340 [TBL] [Abstract][Full Text] [Related]
18. Multiple endocrine neoplasia type 2B mutation in human RET oncogene induces medullary thyroid carcinoma in transgenic mice. Acton DS; Velthuyzen D; Lips CJ; Höppener JW Oncogene; 2000 Jun; 19(27):3121-5. PubMed ID: 10871866 [TBL] [Abstract][Full Text] [Related]
19. RET oncogene puzzle in Chernobyl thyroid tumours. Bonn D Lancet; 1996 Apr; 347(9009):1176. PubMed ID: 8609764 [No Abstract] [Full Text] [Related]
20. C-cell and thyroid epithelial tumours and altered follicular development in transgenic mice expressing the long isoform of MEN 2A RET. Reynolds L; Jones K; Winton DJ; Cranston A; Houghton C; Howard L; Ponder BA; Smith DP Oncogene; 2001 Jul; 20(30):3986-94. PubMed ID: 11494127 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]